Direct Oral Anticoagulants (DOACs) in selected APS patients

Type: drug

Status: FDA Approved (for general anticoagulation, use in APS is off-label or in specific cases)

Developer: Multiple pharmaceutical companies (e.g., Bayer, Bristol-Myers Squibb)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026